Extramedullary involvement in the absence of bone marrow disease is rare in patients with acute promyelocytic leukemia (APL). We report two patients with APL who had central nervous system (CNS) relapse without evidence of cytologic and molecular disease of bone marrow after all-trans-retinoic acid (ATRA) treatment. Both of the patients were treated successfully with combination of intrathecal chemotherapy and radiotherapy with or without systemic chemotherapy. Although increasing number of cases with extramedullary involvement of APL after ATRA including therapy have been reported, further studies with a large series of patients are necessary to determine whether ATRA increases the risk of development of extramedullary involvement of disease in patients with APL.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10245330701442472DOI Listing

Publication Analysis

Top Keywords

extramedullary involvement
12
central nervous
8
nervous system
8
cytologic molecular
8
patients acute
8
acute promyelocytic
8
promyelocytic leukemia
8
bone marrow
8
patients apl
8
patients
6

Similar Publications

MYCN-amplified spinal ependymomas: a rare aggressive subtype. Illustrative cases.

J Neurosurg Case Lessons

January 2025

Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Background: Spinal ependymomas are typically slow-growing tumors with a favorable prognosis. Recently, a new aggressive subtype has emerged with its own distinct histopathological and molecular features characterized by MYCN amplification. However, this subtype of spinal ependymoma is rare, and studies on its imaging characteristics are limited.

View Article and Find Full Text PDF

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Exp Hematol Oncol

January 2025

Bone Marrow Transplantation Center of The First Affiliated Hospital Liangzhu Laboratory, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang, China.

Background: Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited.

Methods: This study aimed to evaluate the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with R/R B-ALL between November 2020 and November 2023 (ChiCTR2100053871). Key endpoints included the adverse event incidence, overall survival (OS), and leukemia-free survival (LFS).

View Article and Find Full Text PDF

Introduction And Importance: Solitary extramedullary plasmacytoma (SEP) is a rare plasma cell neoplasm, constituting around 3 % of plasma cell malignancies. SEP typically presents as a single tumor, either in bone or soft tissue, without systemic disease, and is often misdiagnosed due to its nonspecific symptoms. Diagnosis requires biopsy and extensive imaging studies to exclude multiple myeloma and other malignancies.

View Article and Find Full Text PDF

Background: Extramedullary hemopoiesis (EMH) is a rare condition characterized by abnormal blood cell production outside the bone marrow, commonly occurring in the liver, spleen, lymph nodes, and less frequently in the mediastinum.

Case Presentation: This case involves a 68-year-old male patient who was found to have a posterior mediastinal mass upon examination. A surgical biopsy was performed, and pathological examination confirmed it to be extramedullary hemopoiesis (EMH).

View Article and Find Full Text PDF

We report the case of a 60-year-old man diagnosed with unilateral, solitary, extramedullary plasmacytoma located in the right lacrimal sac fossa, with no systemic involvement. This rare plasma cell dyscrasia is usually found in the respiratory tract. Clinical and radiological features of the mass and histopathological results are described.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!